

CLAIMS:

1. (original) A method to inhibit angiogenesis in vivo, comprising administration of a composition comprising a pharmaceutically effective quantity of an antagonist of EDG-1 signal transduction.
2. (original) The method of claim 1, wherein the composition further comprises at least one additional anti-angiogenic factor.
3. (original) The method of claim 1, wherein the composition further comprises a PI-3-kinase inhibitor.
4. (original) The method of claim 1, wherein the composition further comprises an Akt kinase inhibitor.
5. (original) The method of claim 1, wherein the composition further comprises wortmannin.
6. (original) The method of claim 1, wherein the composition further comprises LY294002.
7. (original) The method of claim 1, wherein the composition further comprises the DNA sequence encoding a mutated EDG-1 receptor.
8. (original) The method of claim 7, wherein the mutated EDG-1 receptor is T236A, R231K or R233K.
9. (original) A method for treatment of unwanted angiogenesis in a human or animal, comprising administration of a composition comprising a pharmaceutically effective quantity of an antagonist of EDG-1 signal transduction.
10. (original) The method of claim 9, wherein the composition further comprises an anti-EDG-1 antibody.

11. (original) The method of claim 10, wherein the anti-EDG-1 antibody is a chicken-anti-human-EDG-1 antibody.

12. (original) The method of claim 10, wherein the anti-EDG-1 antibody is a biologically active fragment.